Welcome to Marinus Pharmaceuticals

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. The Company’s lead product is a first in class therapy for epilepsy. Marinus Pharmaceutica’s investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. The Company is located in Branford, Connecticut.

Latest News Releases
» Marinus Pharmaceuticals Raises $20 Million in Series B Financing
» Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults with Partial Onset Seizures
» Marinus Pharmaceuticals, Inc., Completes Two Phase 2 Milestones for Ganaxolone in Epilepsy
» Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
» Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Adult Partial Seizures
» Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Infantile Spasms
» Marinus Pharmaceuticals completes a $29.4 million Series A financing round
» More Press Releases

Upcoming Events

2009 Marinus Calendar
Apr 25-May 2		American Academy of Neurology Annual Meeting - Seattle, WA
May 5-17		Tenth Anti-epileptic Drug Trials Conference - Coral Gables, FL
Jun 28-Jul 2		8th International Epilepsy Congress - Budapest, Hungary
Nov 5-8		Child Neurology Society Annual Meeting  - Santa Clara, CA

If you’d like to meet the Marinus team at any of the events above please contact us at partnering@marinuspharma.com